Back

Geographic variation in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial

18 May 2025 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Exploring physiological and regional variations in HFpEF Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Muthiah Vaduganathan

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on ventilatory control during low-intensity exercise in heart failure with preserved ejection fraction
Doctor S. Doi (Kawasaki, JP)
Abstract Slides Video
Presentation thumbnail
Superiority of the HFA-PEFF score over the H2FPEF score in detecting pulmonary hypertension related to left heart disease with and without elevated pulmonary artery wedge pressure
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides Video
Presentation thumbnail
Renal denervation for resistant hypertension in aortic coarctation: long-term impact on HFpEF risk and diastolic function
Doctor P. Sagmeister (Leipzig, DE)
Abstract Slides Video
Presentation thumbnail
The reversal of the beneficial effects of the sauna intervention on exercise capacity in patients with HFpEF within a 3-month period. Real-time data collected using wearable technology
Associate Professor T. Bekfani (Magdeburg, DE)
Abstract Slides Video
Presentation thumbnail
Sex-specific performance of HFpEF diagnostic algorithms across two independent cohorts
Doctor A. Achten (Maastricht, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Exploring physiological and regional variations in HFpEF

The Event

Event poster

Heart Failure 2025

18 May 2025 13:00 CET
You may be interested in
thumbnail
Congress Presentation
High-sensitivity cardiac troponin and the effect of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of FINEARTS-HF
thumbnail
Congress Presentation
Efficacy and safety of finerenone according to frailty in patients with heart failure: a prespecified analysis of the FINEARTS-HF trial
thumbnail
Congress Presentation
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources